c-Src associates with and is activated by the ErbB-2 receptor tyrosine kinase, but is unable to bind the EGFR. Although c-Src has been found to interact directly and specifically with the ErbB-2 receptor, the significance of this interaction is unclear. Using both chimeric receptor and site-directed mutagenesis approaches, the region of interaction of c-Src on ErbB-2 was identified. Significantly, EGFR could be converted into a receptor capable of binding c-Src by replacement of a catalytic domain of ErbB-2. We further demonstrated that MDCK cells that express mutant EGFR that are competent in c-Src recruitment lose epithelial polarity in organoid cultures, whereas cells overexpressing the wild-type EGFR retain a polarized phenotype. ErbB-2-dependent activation of c-Src results in disruption of epithelial cell-cell contacts leading to cell dispersal that correlates with the re-localization of phospho-MAPK to focal adhesions. Taken together, these observations suggest that recruitment of c-Src to these closely related EGFR family members plays a critical role in modulating cell polarity.
Introduction
Many human malignancies are caused by the deregulation of growth factor receptors in conjunction with the cytoplasmic signaling molecules that associate with them. Indeed, studies have identified that approximately 30% of all breast cancer cases display an overexpression of the ErbB-2/Neu receptor that correlates with a poor clinical prognosis in both node positive and node negative women (Slamon et al., 1989; Andrulis et al., 1998) . Moreover, between 40 and 60% of Ductal Carcinomas In Situ (DCIS) express high levels of c-ErbB-2 (Latta et al., 2002) .
Direct evidence for the c-ErbB-2/Neu receptor tyrosine kinase (RTK) in transformation stems from numerous studies in cell culture as well as mouse models. For example, elevated expression of an activated version of c-erbB-2/neu in the mouse mammary gland driven by the murine mammary tumor virus (MMTV) promoter induces multifocal adenocarcinomas with rapid onset (Muller et al., 1988; Bouchard et al., 1989) . The potent transforming activity of erbB-2 in the mammary epithelium can be attributed to its capacity to associate with a number of key downstream signaling pathways. For example, in primary human breast cancer samples, at least 70% of the tyrosine kinase activity in the cytosolic fraction is due to c-Src (Ottenhoff-Kalff et al., 1992) . Consistent with these human studies, we have demonstrated that tumors induced by the expression of activated ErbB-2 possess elevated c-Src activity . It has been further demonstrated that the increase in c-Src activity is due to the ability of activated ErbB-2 to form stable complexes with c-Src in an SH2-dependent manner (Luttrell et al., 1994; Muller, 1994, 1995b; BelschesJablonski et al., 2001) . Another striking feature of c-Src association with the EGFR family was that it was restricted to the ErbB-2 receptor and could not directly interact with the closely related EGFR (Muthuswamy and Muller, 1995a, b) . Taken together, these observations argue that c-Src plays a critical role in ErbB-2 mediated transformation. Although the evidence suggests the importance of c-Src in EGFR family mediated mitogenesis and transformation, the specific molecular mechanism of c-Src activation and recruitment is unclear.
To identify the region of interaction of c-Src with ErbB-2, we have employed both chimeric receptor and a site-specific mutagenesis approaches. The results revealed that c-Src associates within the catalytic domain of ErbB-2. We further demonstrated that epithelial cells that express a chimeric EGFR receptor engineered to associate with and activate c-Src lose cell polarity and cell-cell junctions and disperse in response to EGF. Finally we show that the c-Src-dependent dispersal response of epithelial cells is correlated with the relocalization of phospho-MAP kinase to the cytoplasmic membrane. These observations suggest that the ability of ErbB-2 to specifically recruit c-Src results in the breakdown of cell-cell adhesions and dispersal of organized epithelium that could contribute to metastatic invasion.
Results
The carboxyl terminal region does not mediate the association of Src to the ErbB-2 RTK In order to address systematically whether the major autophosphorylation sites on ErbB-2 mediate the association of c-Src to the ErbB-2 RTK, we assessed the ability of c-Src to associate with a series of activated ErbB-2 (NeuNT; Bargmann et al., 1986; Bargmann and Weinberg, 1988 ) mutants harboring individual mutations in each of the known tyrosine autophosphorylation sites (Figure 1a ). Direct binding assays using an Src-SH2 GST fusion protein revealed that the individual removal of any of the five autophosphorylation sites from the NeuNT receptor resulted in the association of the c-Src SH2 domain to the receptor, similar to the association observed with NeuNT ( Figure 1b , lanes 1-7) in a tyrosine phosphorylationdependent manner (Figure 1c, lanes 3-7) . These results suggest that the alteration of any single tyrosine residue tested in the carboxyl terminal region does not affect the association of c-Src to the receptor and that potentially other tyrosine residues may mediate the association with c-Src.
In order to identify whether any of the five major tyrosine autophosphorylation sites can independently mediate the association of c-Src to the NeuNT receptor, mutant ErbB-2 receptors bearing single tyrosine autophosphorylation sites (add-back mutants) were subjected to identical direct binding analysis (Figure 1b , lanes 1, 2, 9-13). The results revealed that all tested ErbB-2 addback mutants were capable of directly binding the c-Src SH2 domain (Figure 1c , lanes 9-13). Significantly, ErbB-2 mutants lacking all of the known tyrosine phosphorylation sites (NT-NYPD) still retained the capacity to bind to the c-Src SH2 domain (Figure 1b , lane 8). Indeed, despite the loss of five major tyrosine phosphorylation sites, the NYPD mutant was efficiently tyrosine phosphorylated ( Figure 1c, lane 8) . To confirm the in vitro binding studies, we also tested whether the NYPD mutant could be co-immunoprecipitated with cSrc. Consistent with the direct binding analyses, c-Src could efficiently associate with the NYPD mutant in vivo (Figure 1d, lane 3) . Taken together, these observations suggest that c-Src interacts with a tyrosine residue on ErbB-2 that is distinct from the five major autophosphorylation sites.
The catalytic domain mediates the association of ErbB-2 with c-Src Previous studies suggested that unlike ErbB-2, c-Src is unable to directly interact with the closely related EGFR (Muthuswamy and Muller, 1995b) . Given the differential binding observed between c-Src and the members of the EGFR family, we took advantage of chimeric receptors between EGFR and ErbB-2 (Figure 2a ) to define the region on ErbB-2 necessary for c-Src Figure 2b , lanes 3-6). Interestingly, the chimeric receptor TK1 that is missing the carboxyl terminal region of the ErbB2 kinase domain does not appear to be able to associate with c-Src (Figure 2b , lanes 7 and 8). While the above data suggests that c-Src physically maps to the catalytic region of the receptor, it may be possible that the kinase activity dictates the specificity of c-Src to the EGFR/ErbB2 chimera by differential phosphorylation of the receptor. To address this, we tested the ability of c-Src to associate with a mutant EGFR (RT) that harbors a single point mutation within its juxtamembrane region that confers an ErbB2-like phenotype in the context of an EGFR kinase domain (Di Fiore et al., 1990) . In contrast to the chimeric receptors harboring the ErbB-2 catalytic domain, the RT mutant failed to associate with c-Src ( Figure 2b , lanes 9 and 10). Given the above data, this suggests that c-Src associates specifically with the kinase domain of ErbB2.
Recruitment of c-Src by the chimeric EGFR disrupts epithelial cell polarity and promotes epithelial cell dispersal
To assess whether the observed capacity of ErbB-2 to recruit c-Src influences epithelial cell polarity and dispersal, we established several independent MDCK cell lines expressing activated c-Src, EGFR or the TK chimeric receptor. Immunoblot analyses with several independent clones of MDCK cells expressing different chimeric receptors revealed that they expressed comparable levels of activated RTKs following stimulation with EGF ( Figure 3d ). To ascertain whether recruitment of c-Src influenced the capacity of these cells to form organized epithelial structures, we examined the behavior of the different MDCK clones in collagen gels following EGF stimulation. Initial comparisons of EGFR and TK expressing clones revealed that in the absence of EGF, the majority of the clones when seeded in collagen gels formed cystic structures that comprise of a single layer of polarized epithelial cells ( Figure 3a ). Upon EGF stimulation, the majority of the EGFR expressing cells retained these cystic structures ( Figure 3a , top panels). In contrast to the EGFR expressing cells, the TK expressing MDCK cells exhibited a dramatic scattering and invasion phenotype in response to EGF ( Figure 3a , bottom panels). Higher magnification of these structures revealed that the TK receptor expressing cells exhibited disorganized and dispersed structures that closely resembled MDCK cells that stably expressed an activated c-Src kinase ( Figure 3b , bottom panels). Quantitative analyses of multiple independent clones confirmed that the majority of MDCK cell lines expressing the TK mutant exhibited a dramatic migratory response following EGF stimulation ( Figure 3c ). Significantly, a high proportion of MDCK cells expressing activated c-Src exhibited a dispersed phenotype following EGF stimulation. In contrast, only a small proportion of MDCK cells expressing the parental EGFR exhibited a dispersed phenotype in response to EGF stimulation ( Figure 3c ). Since expression of activated ErbB-2 in MDCK cells has been previously implicated in the induction of epithelial-to-mesenchymal transition (EMT) (Khoury et al., 2001) , we next determined whether the migratory response of these cells expressing different chimeric EGFR was related to a loss of epithelial cell polarity. To accomplish this, MDCK cells expressing EGFR or the TK mutant were assessed for the presence of the adherens junctional protein, E-cadherin, or the tight junction protein, ZO-1 (Figure 4a ). Examination of MDCK cells expressing EGFR revealed that these cells retained a polarized phenotype in either the absence or presence of EGF, while stimulation of MDCK cells expressing the TK chimeric receptor exhibited the loss of both tight junctions and adherence junctions as determined by the intense cytoplasmic staining of both ZO-1 and E-cadherin (Figure 4a ). These observations suggest that an EGF dependent migratory response exhibited by the MDCK cells expressing the TK chimeric receptor is associated with the breakdown of these important cell junctional complexes. Significantly, the use of the c-Src inhibitor PP2 on cell lines expressing the TK mutant rescue the breakdown of both the adherens junctional protein, E-cadherin and the tight junction protein, ZO-1 in the presence of EGF (Figure 4b ), suggesting the importance of c-Src in ErbB2 mediated EMT response.
Recruitment of c-Src by the chimeric EGFR receptor results in the relocalization of activated MAP kinase to focal adhesions
Given the dramatic impact on the migratory behavior of MDCK cells expressing the TK chimeric receptor, we next examined whether the cellular localization of downstream components of the EGFR signaling cascade were altered as a consequence of the capacity to recruit c-Src. To test this possibility, we assessed both the levels and localization of phosphorylated MAPK in stable MDCK clones expressing the different chimeric EGFR receptors following stimulation with EGF. Measurement of the levels of phosphorylated MAPK after stimulation in the various MDCK clones showed that in clones expressing either the EGFR or TK receptor, phosphorylation of MAPK peaked at 5 min poststimulation (Figure 5a ). The increase in the levels of MAPK phosphorylation was not due to differences in Although these biochemical studies suggested that the kinetics of MAPK activation were comparable in MDCK cells expressing the EGFR or the TK receptor, staining of these cells with antibodies specific to phospho-MAPK revealed a dramatically different cellular localization in MDCK cells expressing the chimeric receptor. In both the parental MDCK and EGFR expressing MDCK cells, phospho-MAPK was initially detected primarily in the nucleus (Figure 5c ). Following 5 min of stimulation, an increase in nuclear localization of phospho-MAPK was noted in both parental and EGFR expressing MDCK cells. In contrast to these results, MDCK cells expressing the TK chimeric receptors possessed the bulk of phospho-MAPK staining at points of focal adhesions at the tips of actin stress fibers in both resting and stimulated cells (Figure 5c ). Thus, similar to rat fibroblasts expressing activated c-Src (Fincham et al., 2000) , the chimeric EGFR that is competent for binding c-Src re-localizes phospho-MAPK to focal adhesions.
Given the above data, it is conceivable that MAPK activity is required for induction of migratory phenotype displayed by the MDCK cells expressing the TK chimeric receptor. To explore this possibility, we assessed whether the potent MEK inhibitor (U0126) could interfere with the capacity of the TK chimera to disrupt cell polarity. EGF stimulation of MDCK or EGFR expressing MDCK cells did not disrupt these cell junction complexes ( Figure 6 ). Additionally, EGF stimulated cells expressing the TK chimera exhibited a dramatic disruption of these cell junction complexes. Remarkably, administration of the U0126 inhibitor completely prevented this disrupted cell architecture ( Figure 6 ). Taken together, these observations argue that the localization and activation of MAPK may be required for the TK receptor to disrupt epithelial cell polarity in response to EGF stimulation.
Discussion
Although previous studies have implicated c-Src as an important mediator of ErbB-2 induced tumorigenesis, the precise mechanism by which this occurred remains to be elucidated. Employing a site-directed mutagenesis and chimeric receptor approach, we demonstrate that cSrc does not associate with any of the phosphotyrosine residues found within the tail of the ErbB-2 RTK but does associate with the carboxyl terminal region of the ErbB-2 catalytic domain. We further demonstrated that recruitment of c-Src to the ErbB-2 catalytic domain resulted in disruption of epithelial cell polarity that is dependent on the re-localization and activation of MAP kinase at focal adhesions. Given the importance of a loss of epithelial cell polarity in metastatic disease processes (Tapon, 2003) , these observations provide a potential molecular explanation for the ability of ErbB-2 to induce metastatic epithelial tumors.
Interestingly, the importance of c-Src association to the catalytic region of an RTK has been previously reported. Studies have shown that c-Src can phosphorylate and associate, albeit weakly, with tyrosine residues in the catalytic domain of the PDGFb receptor (Kypta et al., 1990; Hansen et al., 1996) . Furthermore, the elevated expression of c-Src results in the hyperphosphorylation of tyrosine residues that includes the activation loop of the EGFR , specifically Y845 within the kinase region (Stover et al., 1995) . Within the kinase domain, the activation loop has been found to play an important role in receptor Growth of EGFR or TK expressing MDCK stable clones was treated with either EGF alone or together with EGF and PP2. Structures were immunostained using anti-E-cadherin (red) and anti-ZO-1 (green). Scale bar ¼ 10 mm c-Src interaction with ErbB-2 receptor signaling H Kim et al function, acting much like a molecular gate that permits ATP to enter the binding pocket. Indeed, the activation loop of the insulin receptor harbors three tyrosine residues that are important for the stabilization of the activation loop leading to ATP binding, substrate phosphorylation and full receptor activation (Hubbard et al., 1998) . Interestingly, the region of the kinase domain of ErbB-2 that correlates with c-Src association, referred to as TK2 (Segatto et al., 1991) , harbors the activation loop at tyrosine 882. Significantly, mutation of this residue on ErbB-2 results in the impairment of catalytic activity (Zhang et al., 1998) ; however, mutation of the same tyrosine on EGFR has no significant effect on EGFR activity (Gotoh et al., 1992; Tice et al., 1999 (a) MDCK stable cells were serum-starved overnight then stimulated by the addition of 100 ng/ml of EGF for the indicated times. Phospho-MAPK and total MAPK levels were determined by immunoblot analyses of cell lysates derived from these cultures (Cell Signaling Technology). (b) COS7 cells transiently transfected with either the EGFR or the mutant TK construct were serum starved overnight and stimulated with 100 ng/ml of EGF for the indicated times. Phospho-EGFR, total EGFR, phospho-Src and total Src levels were determined by immunoblot analysis. (c) To track the localization of MAPK proteins in the MDCK cells, parallel cultures of stimulated MDCK cells were also immunostained for phosphop44/42 (pMAPK; red) and actin cytoskeleton (green). Cell nuclei were counterstained with DAPI. Scale bar ¼ 10 mm c-Src interaction with ErbB-2 receptor signaling H Kim et al conjunction with our data suggest that both c-ErbB2 and the EGFR can associate with c-Src, our data also suggest that c-ErbB2 appears to mediate the primary association of c-Src to this receptor family. This model of c-Src mediated RTK activation may have important implications in the capacity of ErbB-2 to serve as the central player in EGFR family signaling (Karunagaran et al., 1995) . The observation that c-Src augments the mitogenic response of cells to EGF (Luttrell et al., 1988; Maa et al., 1995; Belsches et al., 1997; Tice et al., 1999) is consistent with the idea that recruitment of c-Src to ErbB-2/EGFR heterodimers may be a critical step in EGFR transphosphorylation. Another EGFR family member that may be dependent on the ErbB-2/c-Src complex is ErbB-3. In contrast to other EGFR family members, ErbB-3 is naturally catalytically inactive (Guy et al., 1994) and is thus dependent on transphosphorylation by other EGFR family members. As RTK activation is thought to be dependent on the juxtaposition of two competent tyrosine kinase catalytic domains, it is conceivable that the ErbB-2/c-Src complex may serve as an active kinase involved in ErbB-3 transphosphorylation. Indeed, mammary tumors expressing activated ErbB-2 possess high levels of tyrosine phosphorylated ErbB-3 (Siegel et al., 1999) .
Another important finding of our studies is that recruitment of c-Src to the ErbB-2 catalytic domain in the chimeric EGFR mutant (TK receptor) promotes the loss of epithelial polarity in three-dimensional organoid cultures. Notably, the stimulation of MDCK cells expressing the TK receptor resulted in the relocation of E-cadherin and ZO-1 cell junctional proteins to a cytoplasmic compartment, whereas the stimulation of cells expressing EGFR failed to promote the breakdown of cell-cell junctions (Figure 4a ). We further demonstrate that this dramatic disruption of epithelial cell polarity is correlated with the re-localization of phospho-MAP kinase to focal adhesions and is dependent on a functional MEK/MAP kinase cascade (Figure 5c ). Consistent with these observations, previous studies with MDCK or MCF-10A cells engineered to express activated forms of ErbB-2 exhibited alterations in their epithelial morphology (Khoury et al., 2001; Muthuswamy et al., 2001) . Furthermore, activation of ErbB-2 but not the EGFR, in MCF-10A cells, exhibit luminal filling (Muthuswamy et al., 2001) ; however, in contrast to our observations epithelial adherens and tight junctional proteins were maintained (Muthuswamy et al., 2001) . The difference in the phenotypic response to ErbB-2 in the previous study may be due to the regulated generation of ErbB-2 homodimers and subsequent activation (Muthuswamy et al., 2001) , whereas the chimeric EGFR/ErbB-2 receptor is capable of forming heterodimers with other members of the EGFR family. This further suggests that epithelial cell polarity involves the cooperation between ErbB-2 and c-Src signaling and the constellation of signaling molecules coupled to the carboxy-terminus of the EGFR.
The importance of c-Src recruitment to RTKs initiating the disruption of epithelial cell polarity has recently been described for MCF-10A cells expressing activated forms of CSF-1R (Wrobel et al., 2004) . In a similar manner to MDCK cells expressing the TK chimeric receptor, autocrine activation of CSF-1R results in the dramatic relocalization of cell junction proteins to a cytoplasmic compartment that is dependent on the recruitment of c-Src to the activated CSF-1 receptor (Wrobel et al., 2004) . Indeed, EGF stimulation of MDCK cells expressing the TK mutant results in cSrc phosphorylation on tyrosine 416, cell dispersion and the disruption of epithelial cell polarity. Significantly, the inhibition of c-Src in MDCK/TK mutant cells rescues the dispersed phenotype and epithelial cell polarity (Figure 4b ). In addition to the recruitment of c-Src to the TK chimeric receptor, a dramatic relocalization of phospho-MAPK occurs as early as 5 min post-EGF stimulation, from the nuclear compartment to sites of focal adhesion. While, EGF stimulation of both the EGFR and TK/MDCK cells results in a similar phospho-MAPK pattern by 30 min (Figure 5c ), over time a clear difference in morphology develops, that is, TK are dramatically dispersed while EGFR cells retain their parental morphology (Figures 3 and 4a ). Given our biochemical data implicating c-Src in this process in addition to the demonstration that disruption of epithelial cell polarity is dependent on MEK/MAPK signaling, we suggest that c-Src plays an important role in epithelial cell polarity and dispersion mediated by c-ErbB2. Consistent with these results, it has previously been reported that fibroblast cell lines expressing v-Src have re-localized phospho-MAPK to newly formed focal adhesions (Fincham et al., 2000) . More recently, it has been demonstrated that localized c-Src signaling through MAPK regulates adhesion disassembly that is critical in modulating cell migration (Webb et al., 2004) . Given the demonstrated ability of ErbB-2 to promote the migratory behavior of metastatic breast cancer tumor cells, it is conceivable that ErbB-2 mediated relocalization of c-Src and MAPK plays a critical role in modulating the migratory behavior of tumor cells. Future studies with tissue specific ablation of c-Src in these ErbB-2 mammary tumor models should allow these issues to be addressed.
Materials and methods

PCR mutagenesis and DNA constructs
The NeuNT (V664E) cDNA was provided by R Weinberg. The wild-type EGFR and the TMTK, TK, TK1 and RT cDNA constructs were provided by PP Di Fiore. The EGFR and TK cDNA were subsequently cloned into the pcDNA3 expression vector and used to generate MDCK stable cell lines. All autophosphorylation point mutations generated in the context of the NeuNT cDNA and were described previously (Dankort et al., 1997) . All nucleotide primers and sequencing were performed by the MOBIX Central Facility of McMaster University. The phosphoglyceraldehyde kinase-Puromycin plasmid (PGK-Puro) was obtained from MA Rudnicki. The c-SrcSH2 protein was a gift from B Margolis.
Cell lines, transformation assays and collagen assays
Rat1 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum with penicillin, streptomycin and amphotercin B. Stable Rat1 cell lines were established as previously described (Dankort et al., 1997) . RHER (R1/HER) represents a stable fibroblast cell line that overexpresses the EGFR, while the NAFA cell line is a mammary epithelial cell that overexpresses NeuNT. Both have been described previously (Muthuswamy and Muller, 1995b) . COS7 cells were transiently transfected with either the EGFR or TK mutant constructs as per the manufacturers instructions (Lipofectamine, Invitrogen). Subsequent to serum starvation, cells were stimulated with 100 ng/ml EGF for the required times. MDCK cell collagen assays were performed as previously described (Khoury et al., 2001) . Briefly, MDCK cell lines, seeded at a concentration of 10 4 cells/17 mm well, were allowed to form three-dimensional structures for 4-6 days whereupon EGF alone or with inhibitor was added. Medium was changed and U0126 inhibitor (Promega) renewed every 5 days. The assay was fixed and stained after approximately 2 weeks. (Khoury et al., 2001) .
Fluorescent immunostaining and microscopy
Cells were fixed and immunostained following standard procedures. The secondary antibodies, goat anti-mouse (Alexa555 or Alexa488) and goat anti-rabbit (Alexa555 or Alexa488) were purchased from Molecular Probes. All cell images were taken using the Zeiss LSM 510 laser scanning confocal microscope.
Immunoprecipitation, immunoblotting and direct binding assays
Immunoprecipitation analyses were performed on stable cell lines cultured on confluent plates following EGF stimulation (100 ng/ml) for 5 min. All plates were washed twice in ice cold PBS with 1 mM sodium orthovanadate and lysed on ice with 0.7% 3-{(cholamidopropyl)-dimethyl-ammonio}-1-propaneosulphonate (CHAPS) lysis buffer (50 mM Tris HCl pH 8.0, 0.7% CHAPS, 50 mM NaCl, 1 mM sodium orthovanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin) or PLCg lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% Glycerol, 1% Triton X-1, 1% EGTA, 20 mM NaF, 1 mM sodium orthovanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin). Each lysate was cleared by centrifugation for 15 min at 41C. Immunoprecipitations were performed by incubating with the appropriate antibodies: anti-Src (LA074, Quality Biotech; v-Src Ab1, Oncogene Science), anti-EGFR (Transduction Labs) or normal mouse serum (NMS) and protein-G-sepharose for 3 h rotating at 41C and subsequently washed five times with 0.7% CHAPS lysis buffer. Samples were fractionated by SDS-PAGE and transferred onto PVDF membranes.
For immunoblotting the following antibodies were used, anti-phosphotyrosine (PY20 1 : 1000, Transduction Labs); anti-EGFR (E12020 1 : 1000, Transduction Labs); anti-Neu (Ab3 1 : 1000, Oncogene Science); v-Src (Ab1 1 : 1000, Oncogene Science); phospho-MAPK and MAPK (1 : 1000, NEB); phospho-EGFR Y1068 (1 : 1000, NEB); phospho-Src Y416 (1 : 1000, NEB). Direct binding assays have been described previously (Dankort et al., 1997) .
